Antiarrhythmic Drugs

Herausgegeben:Vaughan Williams, E.M.;Mitarbeit:Campbell, T.J.

• Broschiertes Buch

Produktbeschreibung

The development of a new antiarrhythmic drug involves many people with disparate skills. The organic chemist who makes it is guided not only by the structure-action relations of previous compounds, but by anticipation of a requirement for a particular type of action. In fact several of the best-known antiarrhythmics, including lidocaine, mexiletine, amiodarone and verapamil, were originally synthesized for other purposes. Physicians have to determine whether the new drug works, and pharma cologists how it works. For some years I have believed that there was room for a work which could be understood by all these groups and which could enlighten each about the point of view of the others. Thus when I was invited by Springer-Verlag to prepare a volume in their series Handbook of Experimental Pharmacology, I already had a firm conception of what its form should be. In any multi-author work there are two objectives which cannot always readily be reconciled. The first is to select topics which would relate to each other in a coherent manner. to give a logical and orderly shape to the volume as a whole. The second is to offer authors the greatest possible freedom to express themselves as they wish. When the general design was complete, prospective contributors were invited to write specific chapters, being provided with a complete list of their coauthors and chosen topics, so that they could avoid overlap.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Handbook of Experimental Pharmacology 89
• Verlag: Springer / Springer Berlin Heidelberg / Springer, Berlin
• Artikelnr. des Verlages: 978-3-642-73668-1
• Softcover reprint of the original 1st ed. 1989
• Seitenzahl: 700
• Erscheinungstermin: 10. Dezember 2011
• Englisch
• Abmessung: 244mm x 170mm x 38mm
• Gewicht: 1185g
• ISBN-13: 9783642736681
• ISBN-10: 3642736688
• Artikelnr.: 36115402

Inhaltsangabe

1 Cardiac Electrophysiology.- 2 Classification of Antiarrhythmic Actions.- 3 Acute and Chronic Animal Models of Cardiac Arrhythmias.- 4 Classification of Human Arrhythmias.- 5 Successes and Limitations of Antiarrhythmic Drug Therapy.- 6 Distinguishing Potentially Lethal from Benign Arrhythmias.- Antiarrhythmic Therapy.- Class I Agents.- 7 Subclassification of Class I Antiarrhythmic Drugs.- 8 Interaction of Class I Drugs with the Cardiac Sodium Channel.- 9 Clinical Use of Class Ia Antiarrhythmic Drugs.- 10 Clinical Use of Class Ib Antiarrhythmic Drugs.- 11 Clinical Use of Class Ic Antiarrhythmic Drugs.- Class II Agents.- 12a Arrhythmias in the Normal Human Heart.- 12b Adrenergic Arrhythmogenicity.- 13 Antiarrhythmic Properties of Beta-Adrenoceptor Blockade During and After Myocardial Infarction.- Class III Agents.- 14 Class III Antiarrhythmic Action.- 15 Amiodarone: Electropharmacologic Properties.- 16 Sotalol.- 17 Clofilium and Other Class III Agents.- Class IV Agents.- 18 Class IV Antiarrhythmic Agents: Utility in Supraventricular Arrhythmias and Their Proarrhythmic Potential.- Class V Agents.- 19 Specific Bradycardic Agents.- Other Therapies.- 20 Use of Adenosine as an Antiarrhythmic Agent.- 21 Physical and Surgical Treatment of Cardiac Arrhythmias.- Factors Involved in Arrhythmogenesis.- 22 Alpha-Adrenoceptors in Arrhythmogenesis.- 23 Adrenergic Arrhythmogenesis and the Long Q-T Syndrome.- 24a Effects of Cardiac Glycosides at the Cellular Level.- 24b Clinical Efficacy of Cardiac Glycosides for Arrhythmias.- 25 Eicosanoids and Arrhythmogenesis.- 26 Possible Role of Lipids and of Free Radicals in Arrhythmogenesis.- 27 Clinical and Pharmacological Characterization and Treatment of Potentially Malignant Arrhythmias of Chronic Chagasic Cardiomyopathy.- 28 Autonomic Mechanisms in Cardiac Rhythm and Arrhythmias.- Epilogue.- Epilogue.